Leading PARP blocker Lynparza (olaparib) looks set to secure a new marketing authorization in Europe, after a positive scientific opinion. 27 June 2022
After repeated failures to register its Duchenne muscular dystrophy (DMD) drug in the USA, new data suggest PTC Therapeutics (Nasdaq: PTCT) might be about ready 22 June 2022
Roche has won approval from the European Commission (EC) for the use of Polivy (polatuzumab vedotin) in combination with MabThera (rituximab) plus cyclophospham 26 May 2022
Merck & Co’s blockbuster drug Keytruda (pembrolizumab) has been approved by the European Commission alongside chemotherapy as neoadjuvant treatment. 25 May 2022
About 100 generic medicines are set to be suspended from use in Europe, after a scientific panel of the European Medicines Agency reviewed evidence of irregular 23 May 2022
A commercial stage biopharmaceutical R&D company, focused on the development of products that address the medical challenges in the therapeutic area of anti-infectives.